SGO Journal Club: Controversial Topics in Gynecologic Cancer: Heated Intraperitoneal Chemotherapy
Heated intraperitoneal chemotherapy (HIPEC) at the time of tumor debulking for ovarian cancer has at least one randomized prospective trial demonstrating benefit in overall survival. There is conflicting data as to the approach and timing of HIPEC. Concerns exist regarding toxicity and complexity of use. Significant heterogeneity exists amongst providers whether HIPEC is even discussed as a treatment option with patients. This session will address the pro's and con's of HIPEC to provide clarity on its current role.
Michael McHale, MD
University of California San Diego Health
Chad Michener, MD
Renata Urban, MD
University of Washington
Susan Zweizig, MD
UMass Memorial Health Care
Recorded on February 24, 2021.
Not eligible for CE credits.
Keywords: Chemotherapy, Clinical Practice, HIPEC, ovary, Pharmacology, Journal Club, Surgical- Open
Physicians, Trainees, Residents, Fellows, Pharmacists, APPs